Core Viewpoint - Haofan Bio, a leading company in the peptide synthesis reagent sector, was established in December 2003 and went public on July 12, 2023, in Shenzhen, with its headquarters in Suzhou, Jiangsu Province [1] Group 1: Business Overview - Haofan Bio specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks, with a focus on peptide drugs, innovative drugs, and biopharmaceuticals [1] - The company has a differentiated advantage in technology and customer resources [1] Group 2: Financial Performance - In Q3 2025, Haofan Bio reported revenue of 435 million yuan, ranking 24th among 34 companies in the industry, while the industry leader, Changchun High-tech, had revenue of 9.807 billion yuan [2] - The net profit for the same period was approximately 99.24 million yuan, placing the company 16th in the industry, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Haofan Bio's debt-to-asset ratio was 7.86%, significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The company's gross profit margin was 38.75%, which is below the industry average of 70.17%, suggesting room for improvement in profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.14% to 10,000, while the average number of circulating A-shares held per shareholder increased by 19.09% to 4,200.4 [5] - The fifth largest circulating shareholder, Huatai-PB Health Mixed Fund, increased its holdings by 26,430 shares [5] Group 5: Future Outlook - The company is expected to maintain steady growth, with projected net profits of 166 million, 208 million, and 268 million yuan for 2025 to 2027, respectively, and corresponding EPS of 1.54, 1.93, and 2.48 yuan [5] - Haofan Bio has established a presence in over 1,900 pharmaceutical-related enterprises globally and is actively expanding into the European market [5] - The company is enhancing its production capacity through self-built facilities and acquisitions, with ongoing projects in Anhui and Huai'an expected to resolve capacity issues by mid-2026 [5]

Group 1 - The core viewpoint of the news is that Haofan Bio has seen a significant increase in its stock price, rising by 5.33% to 57.15 CNY per share, with a total market capitalization of 6.172 billion CNY as of September 15 [1] - Haofan Bio, established on December 2, 2003, and listed on July 12, 2023, specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] - The revenue composition of Haofan Bio's main business includes peptide synthesis reagents at 81.89%, general molecular building blocks at 10.99%, protein reagents at 6.11%, and other products at 1.01% [1] Group 2 - Among the top circulating shareholders of Haofan Bio, a fund under Huatai PineBridge has entered the top ten, with the Huatai Medical and Health Mixed Fund (470006) holding 602,500 shares, representing 1.5% of the circulating shares [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY, achieving a year-to-date return of 38.91% and a one-year return of 46.74% [2] - The fund manager of Huatai Medical and Health Mixed Fund is Zheng Lei, who has a tenure of 10 years and 276 days, with the fund's total asset scale at 7.072 billion CNY [3]

Core Viewpoint - Haofan Bio experienced a 5.23% increase in stock price, reaching 58.20 CNY per share, with a trading volume of 116 million CNY and a turnover rate of 4.82%, resulting in a total market capitalization of 6.286 billion CNY [1] Company Overview - Suzhou Haofan Bio Co., Ltd. is located at Changting Road 1, Suzhou High-tech Zone, Jiangsu Province, and was established on December 2, 2003. The company went public on July 12, 2023. Its main business involves the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] Shareholder Information - Among the top ten circulating shareholders of Haofan Bio, a fund under Huatai PineBridge holds a position. The Huatai Medical and Health Mixed Fund (470006) entered the top ten circulating shareholders in the second quarter, holding 602,500 shares, which accounts for 1.5% of the circulating shares. It is estimated that the fund has earned approximately 1.7411 million CNY in floating profit today [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY. Year-to-date returns stand at 35.59%, ranking 1703 out of 8254 in its category; the one-year return is 41.87%, ranking 3403 out of 8037; and since inception, the return is 171.31% [2] - The fund manager of Huatai Medical and Health Mixed Fund (470006) is Zheng Lei, who has a cumulative tenure of 10 years and 262 days. The total asset scale under his management is 7.072 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -21.99% [2]